Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism

Science. 2011 Apr 15;332(6027):361-5. doi: 10.1126/science.1192152.

Abstract

Angiotensin II (AngII) mediates progression of aortic aneurysm, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown. We show that loss of AT2 expression accelerates the aberrant growth and rupture of the aorta in a mouse model of Marfan syndrome (MFS). The selective AT1 receptor blocker (ARB) losartan abrogated aneurysm progression in the mice; full protection required intact AT2 signaling. The angiotensin-converting enzyme inhibitor (ACEi) enalapril, which limits signaling through both receptors, was less effective. Both drugs attenuated canonical transforming growth factor-β (TGFβ) signaling in the aorta, but losartan uniquely inhibited TGFβ-mediated activation of extracellular signal-regulated kinase (ERK), by allowing continued signaling through AT2. These data highlight the protective nature of AT2 signaling and potentially inform the choice of therapies in MFS and related disorders.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Aorta
  • Aortic Aneurysm / drug therapy
  • Aortic Aneurysm / metabolism*
  • Aortic Aneurysm / pathology
  • Aortic Aneurysm / prevention & control
  • Aortic Rupture / metabolism
  • Aortic Rupture / pathology
  • Aortic Rupture / prevention & control
  • Disease Models, Animal
  • Disease Progression
  • Enalapril / pharmacology
  • Enalapril / therapeutic use
  • Losartan / pharmacology
  • Losartan / therapeutic use
  • MAP Kinase Signaling System
  • Marfan Syndrome / drug therapy
  • Marfan Syndrome / metabolism*
  • Marfan Syndrome / pathology
  • Mice
  • Mice, Knockout
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Receptor, Angiotensin, Type 2 / genetics
  • Receptor, Angiotensin, Type 2 / metabolism*
  • Signal Transduction*
  • Transforming Growth Factor beta / metabolism

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Receptor, Angiotensin, Type 2
  • Transforming Growth Factor beta
  • Angiotensin II
  • Enalapril
  • Mapk1 protein, mouse
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Losartan